Status:
RECRUITING
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Lead Sponsor:
VA Greater Los Angeles Healthcare System
Conditions:
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen ra...
Detailed Description
The imaging analysis will consist in obtaining quantitative measurements of lesion uptake on the pre- and post-LuPSMA RLT (lesion and whole-body SUVmax, SUVmean and tumor volume) at each time point on...
Eligibility Criteria
Inclusion
- Patients with mCRPC scheduled to undergo LuPSMA RLT.
- Willingness to undergo multiple serial PET/CT scans pre- and post-LuPSMA RLT.
- Ability of providing written informed consent.
Exclusion
- Less than 18 years-old at the time of radiopharmaceutical administration.
- Medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study procedures or compliance.
- Contraindications to LuPSMA RLT.
Key Trial Info
Start Date :
December 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2027
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06706921
Start Date
December 15 2024
End Date
November 1 2027
Last Update
November 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073